Replies to post #4319 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Actually, Aslan, point #3 is not valid as noted in the bottommost paragraph of #msg-21512739:

>>
…glycosylation variants are rarely a cause of immunogenicity. I guess you haven’t followed MAXY, whose raison d’etre is producing such variants deliberately. Immunogenicity is much more likely to be caused of impurities in the manufacturing process, and I addressed this issue from GTC’s perspective in #msg-21459812.
<<

Regards, Dew